Navin Khattry
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Navin Khattry has a total of 329 co-authors. Here are the top co-authors by number of shared publications:
Anant Gokarn
Homi Bhabha National Institute (HBNI), Mumbai, India
35 shared publicationsAkanksha Chichra
BMT Unit, Department of Medical Oncology, Tata Memorial Centre, ACTREC, Navi Mumbai, India
27 shared publicationsLingaraj Nayak
BMT Unit, Department of Medical Oncology, Tata Memorial Centre, ACTREC, Navi Mumbai, India
27 shared publicationsSachin Punatar
BMT Unit, Department of Medical Oncology, Tata Memorial Centre, ACTREC, Navi Mumbai, Maharashtra, India; Homi Bhabha National Institute (HBNI), Mumbai, Maharashtra, India
25 shared publicationsAvinash Bonda
21 shared publications- Sachin Punatar
Department of Medical Oncology,Advanced Centre for Treatment, Research and Education in Cancer (ACTREC) , Tata Memorial Centre, Navi Mumbai, India
21 shared publications
Latest Publications
- Open Access
- 18 September 2026
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 45 (1) , 199
Correction: Novel covalent CDK7 inhibitor potently induces apoptosis in acute myeloid leukemia and synergizes with Venetoclax
- 18 September 2026
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 45 (1) , 199
Open AccessCorrection: Novel covalent CDK7 inhibitor potently induces apoptosis in acute myeloid leukemia and synergizes with Venetoclax
- Open Access
- 2 September 2026
- Published by Springer Nature in Annals of Hematology
Concurrent ETV6::ABL1 and BCR::ABL1 in a rare case of chronic myeloid leukemia: a paradox of imatinib resistance and indolent clinical course
- 2 September 2026
- Published by Springer Nature in Annals of Hematology
Open AccessConcurrent ETV6::ABL1 and BCR::ABL1 in a rare case of chronic myeloid leukemia: a paradox of imatinib resistance and indolent clinical course
- 1 February 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (2) , e2500443
Validation and Refinement of the European LeukemiaNet 2022 Genetic Risk Stratification of AML
PURPOSE: The 2022 European LeukemiaNet (ELN22) genetic risk stratification for AML makes critical changes, including removal of FLT3- internal tandem duplications (ITD) allelic ratio and inclusion of mutations in myelodysplasia-related (MR) genes and in-frame bZIP CEBPA mutations. We evaluated the applicability of ELN22 in a uniformly treated younger AML cohort and explored refinements to improve risk prediction. METHODS: We retrospectively analyzed 473 adult patients with AML treated with intensive therapy. A combination of cytogenetics and next-generation sequencing was used to stratify patients into the ELN17 and ELN22 risk. In addition, we also evaluated leukemic stem cell (LSC) burden at diagnosis and postinduction measurable residual disease by multiparametric flow cytometry. RESULTS: A total of 77 cases (16.3%) were reclassified from ELN17, primarily because of changes associated with FLT3 -ITD, CEBPA , and MR gene mutations. As per ELN22, 56.7% of patients were classified as favorable, 28.3% intermediate, and 15.0% adverse risk. ELN22 adverse-risk patients had significantly inferior overall survival and relapse-free survival compared with intermediate- and favorable-risk patients. High LSC burden at diagnosis, presence of WT1 mutations, and DNMT3A-FLT3 -ITD comutated NPM 1 dichotomized the ELN22 intermediate-risk group. CONCLUSION: We conclude that ELN22 is prognostically valid in intensively treated younger patients with AML. Incorporation of WT1 mutation status, triple-mutated NPM1 , and LSC burden may improve risk stratification, particularly within the heterogeneous intermediate-risk category.
- 1 February 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (2) , e2500443
Validation and Refinement of the European LeukemiaNet 2022 Genetic Risk Stratification of AML
PURPOSE: The 2022 European LeukemiaNet (ELN22) genetic risk stratification for AML makes critical changes, including removal of FLT3- internal tandem duplications (ITD) allelic ratio and inclusion of mutations in myelodysplasia-related (MR) genes and in-frame bZIP CEBPA mutations. We evaluated the applicability of ELN22 in a uniformly treated younger AML cohort and explored refinements to improve risk prediction. METHODS: We retrospectively analyzed 473 adult patients with AML treated with intensive therapy. A combination of cytogenetics and next-generation sequencing was used to stratify patients into the ELN17 and ELN22 risk. In addition, we also evaluated leukemic stem cell (LSC) burden at diagnosis and postinduction measurable residual disease by multiparametric flow cytometry. RESULTS: A total of 77 cases (16.3%) were reclassified from ELN17, primarily because of changes associated with FLT3 -ITD, CEBPA , and MR gene mutations. As per ELN22, 56.7% of patients were classified as favorable, 28.3% intermediate, and 15.0% adverse risk. ELN22 adverse-risk patients had significantly inferior overall survival and relapse-free survival compared with intermediate- and favorable-risk patients. High LSC burden at diagnosis, presence of WT1 mutations, and DNMT3A-FLT3 -ITD comutated NPM 1 dichotomized the ELN22 intermediate-risk group. CONCLUSION: We conclude that ELN22 is prognostically valid in intensively treated younger patients with AML. Incorporation of WT1 mutation status, triple-mutated NPM1 , and LSC burden may improve risk stratification, particularly within the heterogeneous intermediate-risk category.
- Top Cited PapersOpen Access
- 8 January 2026
- Published by Springer Nature in Blood Cancer Journal
- Vol. 16 (1) , 10
Is Less “Sufficient” and “Safe” in the MRD Era - Outcomes of Autologous Stem-Cell Transplant as per Melphalan Dose in Patients with Multiple Myeloma
- 8 January 2026
- Published by Springer Nature in Blood Cancer Journal
- Vol. 16 (1) , 10
Top Cited PapersOpen AccessIs Less “Sufficient” and “Safe” in the MRD Era - Outcomes of Autologous Stem-Cell Transplant as per Melphalan Dose in Patients with Multiple Myeloma
- 7 January 2026
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 26 (4) , e553-e556
MRD Directed Consolidation in Multiple Myeloma—Are We There Yet?
- 7 January 2026
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 26 (4) , e553-e556
MRD Directed Consolidation in Multiple Myeloma—Are We There Yet?
- Open Access
- 1 January 2026
- Published by Asia-Pacific Blood and Marrow Transplantation Group in BLOOD CELL THERAPY / The official journal of APBMT
- Vol. 9 (2) , 77-85
Outcomes of PTCY-Based Haploidentical Transplants and Donor Factors Affecting Outcomes: A 12-year Experience from India
Outcomes of haploidentical transplantation have been reported to be comparable to HLA-matched transplants in several studies; however, data from low- and middle-income countries remain limited. In this retrospective study, we evaluated outcomes of 71 patients who underwent haploidentical transplantation for malignant indications using post-transplant cyclophosphamide (PTCy) between July 2010 and March 2022 and analyzed donor factors influencing outcomes. All patients received peripheral blood stem cell grafts with standard PTCy/calcineurin inhibitor/mycophenolate mofetil prophylaxis. Graft failure occurred in seven patients (9.8%), with a higher incidence observed in those with 0-1 mismatch in the graft versus host direction (p=0.011). The incidences of grade II-IV acute graft versus host disease (GVHD) and chronic GVHD were 42.3% and 47.7%, respectively. Overall transplant related mortality (TRM) was 42.3%. Donor killer-cell immunoglobulin-like receptor haplotype BX with 2DS2 and the Bw6Bw6 ligand in recipients were associated with a reduced risk of relapse. The 5-year overall survival was 31.9%. On multivariate analysis, female donors were associated with improved overall survival (hazard ratio 0.465 [95% confidence interval 0.222-0.974], p=0.042). Transplant outcomes were primarily limited by a high incidence of TRM. These findings warrant validation in larger multicenter studies.
- 1 January 2026
- Published by Asia-Pacific Blood and Marrow Transplantation Group in BLOOD CELL THERAPY / The official journal of APBMT
- Vol. 9 (2) , 77-85
Open AccessOutcomes of PTCY-Based Haploidentical Transplants and Donor Factors Affecting Outcomes: A 12-year Experience from India
Outcomes of haploidentical transplantation have been reported to be comparable to HLA-matched transplants in several studies; however, data from low- and middle-income countries remain limited. In this retrospective study, we evaluated outcomes of 71 patients who underwent haploidentical transplantation for malignant indications using post-transplant cyclophosphamide (PTCy) between July 2010 and March 2022 and analyzed donor factors influencing outcomes. All patients received peripheral blood stem cell grafts with standard PTCy/calcineurin inhibitor/mycophenolate mofetil prophylaxis. Graft failure occurred in seven patients (9.8%), with a higher incidence observed in those with 0-1 mismatch in the graft versus host direction (p=0.011). The incidences of grade II-IV acute graft versus host disease (GVHD) and chronic GVHD were 42.3% and 47.7%, respectively. Overall transplant related mortality (TRM) was 42.3%. Donor killer-cell immunoglobulin-like receptor haplotype BX with 2DS2 and the Bw6Bw6 ligand in recipients were associated with a reduced risk of relapse. The 5-year overall survival was 31.9%. On multivariate analysis, female donors were associated with improved overall survival (hazard ratio 0.465 [95% confidence interval 0.222-0.974], p=0.042). Transplant outcomes were primarily limited by a high incidence of TRM. These findings warrant validation in larger multicenter studies.
- Open Access
Multiple Myeloma in Young Adults—Insights From a Tertiary Care Cancer Centre in India
Background: Multiple myeloma (MM) is primarily a disease of the elderly; data on young patients are limited. Aim: To evaluate the clinical characteristics and outcomes of MM patients aged 40 years. Methods: We retrospectively analyzed newly diagnosed MM patients aged ≤ 40 years between 2013 and 2021. Results: Of 1980 patients screened, 110 (5.5%) were ≤ 40 years (median age 36). Hypercalcemia, renal dysfunction, anemia, and bone lesions (CRAB) were seen in 11.9%, 17.3%, 42.7%, and 92.6% of patients, respectively. More than one‐third had International Staging System (ISS) Stage III, 20.8% had HR cytogenetics and 21.6% had light chain disease (LCD). Macrofocal multiple myeloma (MFMM) seen in 31% of patients. Bortezomib–cyclophosphamide–dexamethasone (VCd) and bortezomib–lenalidomide–dexamethasone (VRd) were the common induction regimens. 26.8% received autologous stem cell transplantation (ASCT). At a median follow‐up of 44.2 months, the median progression free survival (mPFS) was 45.9 months. 1‐, 3‐, and 5‐year PFS rates were 84.9%, 62.2%, and 38.6% respectively. A 3‐year PFS was 83.9% with proteasome inhibitor (PI) and 78.7% with immunomodulatory drug (IMiD) as maintenance therapy. A 5‐year PFS was superior with ASCT (58.5%) versus without (27.8%). Poor PFS was associated with anemia, renal dysfunction, poor performance status, high risk cytogenetics, VCd (vs. VRd), poor response to induction chemotherapy, no maintenance therapy and no ASCT. Conclusion: Young MM patients had encouraging survival outcomes despite resource limitations and limited access to novel agents. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission.
Open AccessMultiple Myeloma in Young Adults—Insights From a Tertiary Care Cancer Centre in India
Background: Multiple myeloma (MM) is primarily a disease of the elderly; data on young patients are limited. Aim: To evaluate the clinical characteristics and outcomes of MM patients aged 40 years. Methods: We retrospectively analyzed newly diagnosed MM patients aged ≤ 40 years between 2013 and 2021. Results: Of 1980 patients screened, 110 (5.5%) were ≤ 40 years (median age 36). Hypercalcemia, renal dysfunction, anemia, and bone lesions (CRAB) were seen in 11.9%, 17.3%, 42.7%, and 92.6% of patients, respectively. More than one‐third had International Staging System (ISS) Stage III, 20.8% had HR cytogenetics and 21.6% had light chain disease (LCD). Macrofocal multiple myeloma (MFMM) seen in 31% of patients. Bortezomib–cyclophosphamide–dexamethasone (VCd) and bortezomib–lenalidomide–dexamethasone (VRd) were the common induction regimens. 26.8% received autologous stem cell transplantation (ASCT). At a median follow‐up of 44.2 months, the median progression free survival (mPFS) was 45.9 months. 1‐, 3‐, and 5‐year PFS rates were 84.9%, 62.2%, and 38.6% respectively. A 3‐year PFS was 83.9% with proteasome inhibitor (PI) and 78.7% with immunomodulatory drug (IMiD) as maintenance therapy. A 5‐year PFS was superior with ASCT (58.5%) versus without (27.8%). Poor PFS was associated with anemia, renal dysfunction, poor performance status, high risk cytogenetics, VCd (vs. VRd), poor response to induction chemotherapy, no maintenance therapy and no ASCT. Conclusion: Young MM patients had encouraging survival outcomes despite resource limitations and limited access to novel agents. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission.
- Open Access
- 31 October 2025
- Published by Springer Nature in Blood Cancer Journal
- Vol. 15 (1) , 1-3
Treatment free remission (TFR) in chronic myeloid leukemia—results, compliance and patterns of failure from a tertiary care cancer centre in India
- 31 October 2025
- Published by Springer Nature in Blood Cancer Journal
- Vol. 15 (1) , 1-3
Open AccessTreatment free remission (TFR) in chronic myeloid leukemia—results, compliance and patterns of failure from a tertiary care cancer centre in India
- Open Access
- 16 July 2025
- Published by Wiley in Cancer Medicine
- Vol. 14 (14) , e71068
Moving Beyond G‐CSF Mobilization—Learning From a 15‐Year Experience of Different Stem Cell Mobilization Regimens in Multiple Myeloma
Background: Stem‐cell mobilization in multiple myeloma is usually done with G‐CSF with or without Cyclophosphamide (Cy) based chemotherapy/Plerixafor. Pre‐clinical data suggest the role of proteasome inhibitors in mobilization. We previously reported that Bortezomib (Bort) when added to a Cy‐based regimen had a better stem‐cell yield. Consequent to favorable results with Bort + Cy‐G‐CSF, we used Bortezomib with G‐CSF too. Hence, four different mobilization regimens were used—Bort + G‐CSF (Group‐1); G‐CSF + Plerixafor (Group‐2); Bort – Cy‐G‐CSF (Group‐3); Cy + G‐CSF (Group‐4). We report here our 15‐year retrospective analysis of these 4 mobilization regimens.Objectives: Primary objective was to determine proportion of patients with CD34+ dose ≥ 5 × 106/kg in first apheresis in various groups. Secondary objectives were to determine median CD34+ dose (×106/kg) in first apheresis, total median CD34+ dose (×106/kg) of all harvests and frequency of mobilization failure. Mobilization failure was defined as total CD34+ dose of < 2 × 106/kg or abandoned harvest attempt at physician's discretion after anticipating a poor collection.Results: All consecutive patients with MM aged 18–65 years who underwent stem‐cell mobilization from September 2007–December 2022 were included. In an intention‐to‐treat analysis, a total 200 patients with 205 mobilization attempts were analysed. The median age of the cohort was 48 years. The percentage of patients who collected ≥ 5 × 106 CD34+ cells/kg in the first apheresis was 26%, 53%, 69%, and 63% in Groups 1–4, respectively (p = 0.0001). The median CD34 yield in the first harvest (×106/kg) was 3.62, 5.20, 6.04, and 6.05 in Groups 1–4, respectively (p = 0.00004). The median total stem‐cell dose collected (×106/kg) was 5.73, 6.17, 9.14, and 8.23 in Groups 1–4, respectively (p < 0.00001). Mobilization failure rates were 7%, 3%, 0%, and 2%, respectively (p = NS).Conclusion: Cyclophosphamide‐based chemo‐mobilization regimens with or without Bortezomib have the advantage of higher total stem‐cell yield, while they are equivalent to G‐CSF + Plerixafor for harvest in a single apheresis. The addition of Bortezomib to Cyclophosphamide may help to increase stem cell yield.
- 16 July 2025
- Published by Wiley in Cancer Medicine
- Vol. 14 (14) , e71068
Open AccessMoving Beyond G‐CSF Mobilization—Learning From a 15‐Year Experience of Different Stem Cell Mobilization Regimens in Multiple Myeloma
Background: Stem‐cell mobilization in multiple myeloma is usually done with G‐CSF with or without Cyclophosphamide (Cy) based chemotherapy/Plerixafor. Pre‐clinical data suggest the role of proteasome inhibitors in mobilization. We previously reported that Bortezomib (Bort) when added to a Cy‐based regimen had a better stem‐cell yield. Consequent to favorable results with Bort + Cy‐G‐CSF, we used Bortezomib with G‐CSF too. Hence, four different mobilization regimens were used—Bort + G‐CSF (Group‐1); G‐CSF + Plerixafor (Group‐2); Bort – Cy‐G‐CSF (Group‐3); Cy + G‐CSF (Group‐4). We report here our 15‐year retrospective analysis of these 4 mobilization regimens.Objectives: Primary objective was to determine proportion of patients with CD34+ dose ≥ 5 × 106/kg in first apheresis in various groups. Secondary objectives were to determine median CD34+ dose (×106/kg) in first apheresis, total median CD34+ dose (×106/kg) of all harvests and frequency of mobilization failure. Mobilization failure was defined as total CD34+ dose of < 2 × 106/kg or abandoned harvest attempt at physician's discretion after anticipating a poor collection.Results: All consecutive patients with MM aged 18–65 years who underwent stem‐cell mobilization from September 2007–December 2022 were included. In an intention‐to‐treat analysis, a total 200 patients with 205 mobilization attempts were analysed. The median age of the cohort was 48 years. The percentage of patients who collected ≥ 5 × 106 CD34+ cells/kg in the first apheresis was 26%, 53%, 69%, and 63% in Groups 1–4, respectively (p = 0.0001). The median CD34 yield in the first harvest (×106/kg) was 3.62, 5.20, 6.04, and 6.05 in Groups 1–4, respectively (p = 0.00004). The median total stem‐cell dose collected (×106/kg) was 5.73, 6.17, 9.14, and 8.23 in Groups 1–4, respectively (p < 0.00001). Mobilization failure rates were 7%, 3%, 0%, and 2%, respectively (p = NS).Conclusion: Cyclophosphamide‐based chemo‐mobilization regimens with or without Bortezomib have the advantage of higher total stem‐cell yield, while they are equivalent to G‐CSF + Plerixafor for harvest in a single apheresis. The addition of Bortezomib to Cyclophosphamide may help to increase stem cell yield.
- 23 May 2025
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 25 (9) , e675-e684
Clinical Perspectives on Amyloidosis in India: A Systematic Literature Review
- 23 May 2025
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 25 (9) , e675-e684
Clinical Perspectives on Amyloidosis in India: A Systematic Literature Review